Elan Corporation
-
Jun-12-2002
- Elan Announces New Management Structure Company to Eliminate Divisional Structure
-
Jun-10-2002
- Elan Implements Action Plan to Streamline Operations And Strengthen Corporate Governance
-
Jun-6-2002
- Elan Answers Investors Questions
-
May-16-2002
- Elan Confirms Date for Annual General Meeting and Second Quarter Results
-
May-2-2002
- Elan Reports First Quarter 2002 Financial Results
-
Apr-22-2002
- Elan Announces Webcast of First Quarter 2002 Financial Results
-
Apr-8-2002
- Berna and Iomai Announce Collaboration for Patch Delivery of Vaccines
-
Mar-28-2002
- Elan and UCB Announce Agreement to Co-Promote New Migraine Drug FROVA (TM)
-
Mar-21-2002
- Elan Receives FDA Approval of AVINZA(TM) A Once-Daily Capsule for Chronic, Moderate-to-Severe Pain
-
Mar-1-2002
- Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration
-
Feb-7-2002
- Elan Announces Commencement of SEC Investigation
-
Feb-6-2002
- Elan Responds to Class Action Lawsuits; Plans to Vigorously Defend
-
Feb-4-2002
- Elan Reports 2001 Financial Results
-
Jan-30-2002
- Elan Refutes Wall Street Journal Story; Says Issues Raised Are Historical
-
Jan-28-2002
- Elan Responds to Recent Stock Activity - Confirms Consensus Estimates for 2001 -
-
Jan-28-2002
- Elan Announces Webcast of Fourth-Quarter and Full-Year 2001 Financial Results
-
Jan-17-2002
- Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792
-
Dec-20-2001
- AHP and Elan Create Alliance in the Treatment of Sleep Disorders
-
Dec-18-2001
- Elan and Biogen Begin Phase III Clinical Trials of Antegren(R) (Natalizumab) In Multiple Sclerosis and Crohn's Disease
-
Nov-29-2001
- Elan Announces Appointment of Philip Chaikin, Pharm.D., M.D. as Vice President of Oncology Research & Development
-
Nov-13-2001
- Elan Announces Appointment of Senior Management Personnel
-
Nov-9-2001
- FDA Approves Elan's Migraine Drug Frova(TM) (frovatriptan succinate)
-
Nov-1-2001
- Athena Diagnostics Files Registration Statement for Initial Public Offering
-
Oct-25-2001
- Elan Reports Record Third Quarter Results
-
Sep-19-2001
- Elan Reaffirms Positive Outlook For Third Quarter of 2001 and Full Year 2001
-
Sep-15-2001
- Biogen and Elan Present Promising Data for Antegren(R) (Natalizumab) in Multiple Sclerosis at Ectrims Congress
-
Jul-24-2001
- Elan Reports Record Second Quarter 2001 Financial Results - Total Revenue Up 25% - Product Revenue Up 48% - Diluted Per Share Income Before Other Charges Of 45 Cents for the Quarter an Increase of 45%
-
Jul-5-2001
- Thomas Lynch Appointed Executive Vice Chairman, and Shane Cooke Appointed Executive Vice President and Chief Financial Officer, Elan Corporation, plc
-
May-10-2001
- Botulinum Toxin Type B Studies Demonstrate Long-Term Stability and a Consistent and Pure Formulation
-
May-9-2001
- Elan Exploring Potential Use of MYOBLOC(TM) (Botulinum Toxin Type B) in Spasticity, Pain and Dermatologic Applications
-
May-8-2001
- Potamkin Prize Awarded to Elan Alzheimer's Scientist
-
Apr-23-2001
- Elan Reports Record First Quarter 2001 Financial Results
-
Mar-28-2001
- Elan Announces Plans for European Launch of Myocet(TM) And Initial Payment on Contingent Value Rights (Nasdaq: LCVRZ)
-
Feb-6-2001
- Athena Neurosciences Announces Redemption of Its 4.75% Exchangeable Notes
-
Feb-6-2001
- Elan Corporation, plc Announces Proposed Public Offering of Senior Notes
-
Jan-29-2001
- Elan Reports Record 2000 Financial Results
-
Jan-25-2001
- Elan Corporation, plc and Cambridge Antibody Technology Create Major Alliance For Human Monoclonal Antibodies in Neurological Disease
-
Jan-22-2001
- Elan and Biogen Announce Positive Phase II Results For Antegren(R) (Natalizumab) in Multiple Sclerosis and Crohn's Disease
-
Jan-18-2001
- Elan Announces New Organisation of Its Elan Pharmaceuticals Division
-
Jan-8-2001
- Elan Named on Forbes Global Annual A-List
-
Jan-8-2001
- Elan Named on Forbes Global Annual A-List
-
Jan-5-2001
- Elan Updates Plans for European Launch of Myocet(TM) And Payment of Contingent Value Rights (Nasdaq: LCVRZ)
-
Dec-21-2000
- Elan Reaffirms Positive Outlook for Remainder of 2000 and Calendar Year 2001
-
Dec-11-2000
- FDA Approves Elan's MYOBLOC(TM)
-
Nov-10-2000
- Elan Completes Acquisition of DURA
-
Nov-6-2000
- European Approval Recommended For Elan's NeuroBloc(R); First New Cervical Dystonia Treatment in Over a Decade
-
Oct-19-2000
- Elan Announces Record Third Quarter 2000 Results
-
Sep-11-2000
- Elan to Acquire Dura
-
Aug-30-2000
- Elan Announces First U.S. Approval for Its NanoCrystal(TM) Technology
-
Aug-9-2000
- Elan and Pharmacia Form Alzheimer's Disease Research Collaboration In the Area of Beta-Secretase
More news from PR Newswire...